NEW YORK (Reuters Health) – After platinum failure in patients with advanced non-small-cell lung cancer, adding aflibercept to standard second-line docetaxel treatment does not improve overall survival (OS),…
NEW YORK (Reuters Health) – In the first-line treatment of advanced colorectal cancer, the combination of cediranib and chemotherapy is comparable to bevacizumab plus chemotherapy in terms of…
NEW YORK (Reuters Health) – The risk of developing lung cancer is significantly lower in people with excess body weight compared to those of normal weight, according to…
NEW YORK (Reuters Health) – Patients with esophageal cancer appear to have equally good survival after minimally invasive esophagectomy (MIE) or traditional open surgery, according to a new…
NEW YORK (Reuters Health) – In women with hormone-receptor-positive metastatic breast cancer, combining anastrozole and fulvestrant extends progression-free and overall survival, according to a paper released online today…
NEW YORK (Reuters Health) – Adding gemtuzumab ozogamicin (GO) to induction chemotherapy improved survival in older patients with acute myeloid leukemia (AML), with no apparent additional toxicity, in…
Stacy Loeb, MD discusses how the decision for prostate cancer screening should be an individual one, rather than population-based. Individual risk factors including age, general health, family history,…
It’s highly debated whether patients undergoing radiation therapy for prostate cancer should also have their lymph nodes treated. Janna Andrews, MD, discusses the RTOG trials and their results, which…
Charles Jungreis, MD, Chairperson, Department of Radiology, Professor, Temple University School of Medicine, discusses stereotactic radiosurgery. References and Resources Cesaretti JA, Pennathur A, Rosenstein BS, Swanson SJ, Fernando…
Dr. Francis Cordova, Medical Director of the Lung Transplantation Program at Temple University School of Medicine, discusses the factors that determine strong and weak candidates for lung transplantation…
